Latest Insider Transactions at Evommune, Inc. (EVMN)
This section provides a real-time view of insider transactions for Evommune, Inc. (EVMN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Evommune, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Evommune, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2025
|
Robert Lorne Hopfner Director |
BUY
Open market or private purchase
|
Indirect |
1,000
+19.9%
|
$17,000
$17.35 P/Share
|
|
Dec 09
2025
|
Kyle Carver Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,290
-17.53%
|
$225,930
$17.84 P/Share
|
|
Dec 09
2025
|
Janice Suzann Drew EVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
5,074
-6.96%
|
$86,258
$17.84 P/Share
|
|
Dec 09
2025
|
Gregory S. Moss Chief Business & Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,624
-18.3%
|
$231,608
$17.84 P/Share
|
|
Dec 09
2025
|
Jeegar Pravinkumar Patel Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,513
-13.16%
|
$127,721
$17.84 P/Share
|
|
Dec 09
2025
|
Luis C. Pena President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
28,138
-4.12%
|
$478,346
$17.84 P/Share
|
|
Dec 09
2025
|
Eugene Bauer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,478
-0.54%
|
$25,126
$17.84 P/Share
|
|
Nov 07
2025
|
Pivotal Bio Venture Partners Fund I, L.P. Director |
BUY
Conversion of derivative security
|
Indirect |
3,367,975
+50.0%
|
-
|
|
Nov 07
2025
|
7 Cooperative Ua Lsp |
BUY
Open market or private purchase
|
Direct |
1,562,500
+24.07%
|
$25,000,000
$16.0 P/Share
|
|
Nov 07
2025
|
7 Cooperative Ua Lsp |
BUY
Conversion of derivative security
|
Direct |
3,367,133
+50.0%
|
-
|
|
Nov 07
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+20.39%
|
$20,000,000
$16.0 P/Share
|
|
Nov 07
2025
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,208,770
+50.0%
|
-
|
|
Nov 07
2025
|
Eugene Bauer Chief Medical Officer |
BUY
Conversion of derivative security
|
Direct |
25,812
+8.66%
|
-
|
|
Nov 07
2025
|
Robert Lorne Hopfner Director |
BUY
Conversion of derivative security
|
Indirect |
3,371,001
+50.0%
|
-
|
|
Nov 07
2025
|
Gregory S. Moss Chief Business & Legal Officer |
BUY
Conversion of derivative security
|
Indirect |
3,175
+50.0%
|
-
|
|
Nov 07
2025
|
Jeegar Pravinkumar Patel Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
3,175
+5.27%
|
-
|
|
Nov 07
2025
|
Luis C. Pena President & CEO |
BUY
Conversion of derivative security
|
Direct |
24,225
+3.43%
|
-
|
|
Nov 07
2025
|
Weegen Felice Isabel Verduyn Van |
BUY
Open market or private purchase
|
Indirect |
1,562,500
+24.07%
|
$25,000,000
$16.0 P/Share
|
|
Nov 07
2025
|
Weegen Felice Isabel Verduyn Van |
BUY
Conversion of derivative security
|
Indirect |
3,367,133
+50.0%
|
-
|
|
Nov 07
2025
|
Kyle Carver Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
3,175
+4.02%
|
-
|
|
Nov 07
2025
|
David E Cohen |
BUY
Conversion of derivative security
|
Direct |
6,056
+20.38%
|
-
|
|
Nov 07
2025
|
Janice Suzann Drew EVP, Operations |
BUY
Conversion of derivative security
|
Direct |
1,587
+2.13%
|
-
|